Scarica l'app Stockscreener
254.69
9.08%
-25.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$280.12
Aprire:
$261.69
Volume 24 ore:
679.78K
Relative Volume:
2.22
Capitalizzazione di mercato:
$6.87B
Reddito:
$2.58B
Utile/perdita netta:
$759.90M
Rapporto P/E:
9.1232
EPS:
27.9168
Flusso di cassa netto:
$374.60M
1 W Prestazione:
-11.52%
1M Prestazione:
-8.50%
6M Prestazione:
-20.30%
1 anno Prestazione:
+5.93%
Intervallo 1D:
$242.28
$264.22
Intervallo di 1 settimana:
$242.28
$294.05
Portata 52W:
$211.43
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Nome
Bio Rad Laboratories Inc
Settore
Industria
Telefono
(510) 724-7000
Indirizzo
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
254.54 | 7.54B | 2.58B | 759.90M | 374.60M | 27.92 |
ABT
Abbott Laboratories
|
89.81 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
298.62 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.48 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.86 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.44 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-03 | Downgrade | Citigroup | Buy → Neutral |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-06-16 | Iniziato | Wells Fargo | Overweight |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-01-28 | Reiterato | Citigroup | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2018-10-17 | Iniziato | Goldman | Buy |
| 2018-09-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Downgrade | CL King | Buy → Neutral |
| 2017-07-13 | Iniziato | Wells Fargo | Outperform |
| 2017-06-28 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Hold |
| 2016-10-13 | Iniziato | CL King | Buy |
| 2015-05-06 | Reiterato | Jefferies | Buy |
| 2009-12-18 | Iniziato | Maxim Group | Buy |
| 2009-11-06 | Iniziato | Jefferies & Co | Buy |
| 2009-07-17 | Iniziato | Soleil | Buy |
| 2007-09-26 | Iniziato | Banc of America Sec | Buy |
| 2007-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mostra tutto
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption - MSN
Bio-Rad Laboratories Q1 2026 Earnings Call Transcript - MarketBeat
Bio-Rad Laboratories Inc (BIO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Bio-Rad Laboratories Q1 Earnings Call Highlights - Yahoo Finance
BIO SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
MSN Money - MSN
Bio-Rad (BIO) Reports Strong Q1 Revenue Amidst Market Challenges - GuruFocus
Bio-Rad Q1 2026 slides: earnings beat masks currency headwinds - Investing.com
Bio-Rad Laboratories (BIO) Lags Q1 Earnings Estimates - Yahoo Finance
Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus
Bio-Rad Laboratories Reports Q1 2026 Results, Cuts Outlook - TipRanks
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call - Benzinga
Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss - Quiver Quantitative
Bio-Rad Laboratories Q1 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Bio-Rad: Q1 Earnings Snapshot - KTVB
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Huge Sartorius loss drives Bio-Rad (NYSE: BIO) Q1 2026 net loss - Stock Titan
Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance - Stock Titan
Bio-Rad Reports First-Quarter 2026 Financial Results - Business Wire
Bio-Rad earnings on deck: Can margin recovery offset academic headwinds? - Investing.com Australia
Bio-Rad earnings on deck: Can margins recover after rough 2025? - Investing.com Canada
Food Diagnostics Market to Reach USD 32.8 Billion by 2033 at 9.0% - openPR.com
Transcriptomics Technologies Market to Reach USD 20.64 Billion - openPR.com
Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers - News-Medical
Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding - Stock Titan
Bio-Rad (BIO) EVP Courtney Enloe gains shares via RSU vesting, withholds for taxes - Stock Titan
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report - GlobeNewswire
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report 2025-2034 Featuring Roche, Danaher, Abbott Laboratories, Thermo Fischer Scientific, Bio-Rad Laboratories, Sysmex, BD & Co, and Biomerieux - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential - DirectorsTalk Interviews
Citigroup downgrades Bio-Rad Laboratories (BIO) - MSN
Bio-Rad Laboratories, Inc. Amends 2017 Incentive Award Plan and Updates Entity Information in April 2026 8-K Filing - Minichart
Bio-Rad Laboratories (BIO.US) will release its earnings report after the market closes on April 30. - Moomoo
Bio-Rad Laboratories Stockholders Approve Directors and Governance Items - TipRanks
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes - Stock Titan
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns - Yahoo Finance
Bio-Rad Laboratories Inc (BIO) Shares Fall 6.4% -- What GF Score of 77 Tells Investors - GuruFocus
Greg K. Hinckley adds Bio-Rad (BIO) shares through RSU vesting and grant - Stock Titan
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and receives 369-unit grant - Stock Titan
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and gains 369 new units - Stock Titan
Bio-Rad (BIO) director Arnold Pinkston gains shares, receives new RSU grant - Stock Titan
9 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey
Electroporation Instruments Market is expected to Hit US$ - openPR.com
Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Thursday - MarketBeat
Boston Trust Walden Corp Lowers Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap UpHere's Why - MarketBeat
DNA Extraction, Isolation and Purification Market: Key Players - openPR.com
Metagenomics Market Key Companies AnalysisMerck KGaA, Thermo - openPR.com
Digital PCR Market Set for Strong Growth to US$ 1.45 Billion - openPR.com
Cell Identification Technology Market Is Going to Boom Rapidly | - openPR.com
dPCR Market Will Generate Booming Growth Opportunities to 2031 | - openPR.com
Bio Rad Laboratories Inc Azioni (BIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.70%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):